Follow us...

 

Search News Archives

Monthly Newsletter

 

Lab Bulletin August Newsletter

view the latest issue

Subscribe

News Channels

 

New Laboratory Products

 

Lab News

 

Microscopy & Image Analysis

 

Separation Science

 

Research & Case Studies

 

Literature

 

Videos

 

Events | Webinars

 

 

 

Conferences | Events

UMC Utrecht and Quirem Medical to Collaborate on the Development of Holmium Microspheres for Image-Guided Cancer Treatment

publication date: May 20, 2014
 | 
author/source: UMC Utrecht

Over the next few years, the University Medical Center (UMC) Utrecht and Quirem Medical will be working closely together to maximize the benefits of using holmium microspheres to treat liver cancer patients worldwide.

UMC Utrecht logoThe unique properties of holmium microspheres will enable effective treatment planning, dosimetry en treatment evaluation, thereby further improving the results of patients who undergo radioembolization. The collaboration will cover ongoing and future clinical research, grant applications, the production of holmium microspheres and the application for CE marking. Financial details of the deal were not disclosed.

Image-guided radioembolization of liver tumors

Holmium microspheres are unique in that they can easily be seen on either a SPECT or an MRI scan, allowing the doctor to establish whether the microspheres are doing their work in the right place in the body. There are two stages to a treatment using holmium microspheres. Administering a safe low dosage first, the doctor ascertains whether the radioactivity is accumulating properly in the liver. If it is, a higher dosage is administered. Holmium treatment is currently only applied in a palliative care setting

Clinical research

The results of a phase I clinical study (HEPAR I) were published in Lancet Oncology in 2012. As part of that study, UMC Utrecht researchers treated 15 patients and found that the treatment was safe. A clinical study (the HEPAR II study) one the effectiveness and to collect further support for the safety of the treatment is currently ongoing. This study will see 40 new patients being treated at UMC Utrecht.

Prof. Maurice van den Bosch, an interventional radiologist at UMC Utrecht, says, “To transform academic research in medicine from new and exciting ideas into innovations that can make a real difference to how we treat patients requires the long and firm commitment of both public and private partners. In Quirem Medical we have found a strong and dedicated partner that will further expedite the use of our research efforts in the field of minimally invasive, image-guided cancer treatments.”

Jan Sigger, CEO of Quirem Medical, adds, “We are very pleased to have UMC Utrecht as our collaboration partner for the further development of the holmium radioembolization procedure. UMC Utrecht’s strong imaging and interventional capabilities are very much in line with the options that QuiremSpheres® can provide to improve the effectiveness of the radioembolization procedure and, as a result, patient outcome.”

Founded in 2013 as a UMC Utrecht spin-off, Quirem Medical is an emerging medical device company that seeks to develop the next generation of microspheres for the targeted interventional treatment of liver malignancies. The unique properties of its holmium-based particles (QuiremSpheres™) make radioembolization treatments more effective. Whether using SPECT or MRI, the imaging and dose quantification options that the particles provide ensure optimally accurate treatment planning and evaluation. Quirem’s ambition is to provide a real-time, image-guided, personalized radioembolization treatment that improves patient outcome and increases the use of this innovative technology.


About University Medical Center Utrecht

University Medical Center Utrecht (UMC Utrecht) belongs to the largest public healthcare institutions in the Netherlands. It was created in 2000 through the merger of Utrecht Academic Hospital, Wilhelmina Children’s Hospital and the Medical Faculty of Utrecht University. UMC Utrecht has the ambition to be a leading international healthcare provider, medical school and research institute that is exciting for its people, attractive to talent and embodies a culture of teamwork, innovation, sustainability and high performance. As a patient-centered organization, its 11,000 employees are dedicated to prevent disease, improve healthcare, develop new treatment methods and refine existing ones, with patient safety and quality as cornerstones. Strategic research programs are Brain, Child Health, Circulatory Health, Infection & Immunity, Personalized Cancer Care and Regenerative Medicine & Stem Cells. UMC Utrecht is embedded in a vibrant and entrepreneurial science community where knowledge about health, disease and healthcare is generated, validated, shared and applied


more about umc utrecht


 



 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd

 


Promotions

 

Media Partners